Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Autoria(s):
Post F.A.; Moyle G.J.; Stellbrink H.J.; Domingo P.; Podzamczer D.; Fisher M.; Norden A.G.; Cavassini M.; Rieger A.; Khuong-Josses M.A.; Branco T.; Pearce H.C.; Givens N.; Vavro C.; Lim M.L.
